A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to ...

Sales of Zepbound and Mounjaro soared during the second quarter, easily beating Wall Street estimates and widening the gap ...

Eli Lilly (LLY) stock jumps as the firm posts better-than-expected Q2 2026 results, driven by its injectable GLP-1s and its ...

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may ...

Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street ...

CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its ...

CNBC's Annika Kim Constantino joins 'Squawk on the Street' to discuss Eli Lilly's Q2 results and why the company is ...

Compared to the overall stock market, Eli Lilly(NYSE: LLY) has delivered some fairly ho-hum year-to-date returns, rising just ...

And it will likely be the first company in the sector to get there.

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Eli Lilly and Co posted better-than-expected quarterly results and raised ...